Technology Overview















Presbyopia is a condition in which, as a person ages, the human eye exhibits a progressively diminished ability to focus on near objects such as reading or using a Smart Phone. It is mainly caused by a loss of elasticity of the crystalline lens, which is the focusing mechanism of the eye. Presbyopia is caused mainly by the unimpeded growth of the crystalline lens. Each lens grows uniquely, but exhibits a pattern whereby new cells grow around the outside of the lens while pushing the old cells to the middle. Because the lens never sloughs off any of its cells, the process ultimately leads to a structural breakdown of the lens and its ability to accommodate from near to far objects.

The first signs of presbyopia are usually noticed between the ages of 35-45 and typically include eyestrain, difficulty seeing in dim light, and problems focusing on small objects and fine print. Generally, presbyopia affects everyone in the subject age group and progresses throughout life until leveling off at about age 60

LRG’s technology engages a real-time System approach utilizing a premium multi photon (MPM) imaging technology for both targeting and treatment. 

  • The advantage of MPM is to use a non-linear beam to view to the single micron level. Then once targeted the energy level of the fs laser may be merely increased to eliminate the appropriate cells. An additional major advantage of MPM is the minimal collateral damage. In linear laser application there is substantial damage to tissue anterior and posterior to the specific target, the Gaussian effect. In non-linear laser application, the beam is split and rejoins at the specific target and therefore, there is little Gaussian effect.
  • Laser ablation is the process of removing material from a surface by irradiating it with a laser beam. Both Pico and Femtosecond lasers are already in widespread use in ophthalmology, and are commonly utilized for refractive surgical correction procedures, such as LASIK. LRG’s concept, supported by its research to date, indicates that ablating the epithelial cells will significantly diminish cellular growth within the crystalline lens, substantially delaying/stopping the onset, and progress, of presbyopia.

LRG’s presbyopic treatment is non-invasive, and could be performed in a physician’s office, in about an hour, which would avoid the time and cost of using a Surgery Center or an Operating Room environment. There would be no flap to lift or replace and none of the pre and post treatment regimen necessary with LASIK or PRK. The only requirement is maximum dilation. Post treatment, it is likely there would be a short term application of a topical steroid medication to minimize any potential for an inflammatory response.

In the spring of 2013, LRG completed a study with the goal to establish LRG’s ability to image and treat cells on the anterior surface of the lens. Fifty-four porcine cadaver lenses were used for imaging and/or treatment. Not only did LRG demonstrate the ability to image single cells on the surface of the lens, but the Company also demonstrated its ability to target and eliminate those cells without any collateral damage.